Table 2.
Sample no. | Before treatment | DMSO | PurB | ||
---|---|---|---|---|---|
No. of somites | No. of somites | Phase | No. of somites | Phase | |
(A) | |||||
1 | 6.5 | 8 | Ph2 | 7 | Ph3 |
2 | 4.5 | 6.5 | Late Ph1 | 6.5 | Ph3 |
3 | 4.5 | 7.5 | Ph3 | 6.5 | Ph2 |
4 | 6 | 8 | Early Ph2 | 8 | Early Ph2 |
5 | 8.5 | 11 | Ph3 | 11 | Ph3 |
6 | 6 | 9 | Ph3 | 9 | Ph3 |
7 | 7 | 9 | Early Ph2 | 9 | Early Ph2 |
8 | 6 | 7 | Ph3 | 7 | Ph3 |
9 | 6 | 7 | Late Ph3 | 6 | Late Ph2/early Ph3 |
10 | 6 | 7 | Ph2 (new cycle) | 7 | Ph3 (previous cycle) |
11 | 6 | 7 | Ph3 | 7 | Ph3 |
12 | 4.5 | 5.5 | Ph3 | 5.5 | Ph3 |
13 | 4 | 5 | Ph3 | 5 | Ph3 |
14 | 6 | 7 | Ph3 | 6 | Ph2 |
15 | 6 | 7 | Ph3 | 6 | Ph3 |
16 | 5.5 | 8 | Late Ph1 | 7 | Late Ph1 |
17 | 7 | 9 | Ph2 | 8 | Ph2 |
18 | 5 | 6 | Ph2 | 5 | Ph2 |
Sample no. | Before treatment | DMSO | RO‐3306 | ||
---|---|---|---|---|---|
No. of somites | No. of somites | Phase | No. of somites | Phase | |
(B) | |||||
1 | 6 | 8 | Ph3 | 7 | Ph2 |
2 | 3.5 | 5 | Late Ph3 | 4 | Late Ph2/early Ph3 |
3 | 5.5 | 7 | Ph2 (new cycle) | 7 | Ph3 |
4 | 5 | 6 | Ph3 | 6 | Ph2 |
5 | 3.5 | 6 | Ph3 | 4 | Ph2 |
6 | 4 | 6 | Ph3 | 5 | Ph3 |
7 | 5 | 7 | Ph3 | 7 | Ph3 |
8 | 4 | 6 | Ph3 | 6 | Ph3 |
9 | 4 | 6 | Early Ph3 | 5 | Ph2 |
10 | 4.5 | 6 | Ph3 | 6 | Ph3 |
Summary table of number of somites and clock delays before and after treatment with Purvalanol B (A) and RO‐3306 (B) inhibitors, compared to DMSO, in E10.5 mouse explants.